ClinicalTrials.gg
CompletedNCT00761735Updated Apr 4, 2017Results posted

5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)

A Phase 3 interventional study of Peginterferon alfa-2b and Ribavirin in Hepatitis C, Chronic, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-04-04.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
94
Allocation
Not applicable
Ages
3 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Hepatitis C, Chronic.

Enrollment
21st of 39
94 · median 99
Started
2007
with 3 others
Phase 3
22 of 40
none open now
Registered
27th of 40
by date
Lead sponsor
25 of 40
Merck Sharp & Dohme LLC

Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, this one is the 21st largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2007, is one of 22 in phase 3, and was the 27th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2b

peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 3 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic as a file.
02

Study summary

Study P02538 Part 2 is a 5-year long term follow-up (LTFU) study in pediatric participants who were treated with at least one dose of peginterferon alfa-2b (PEG-IFN) and ribavirin (RBV) and who completed the follow-up in the P02538 Part 1 study (NCT00104052). No study drug therapy will be administered during the P02538 Part 2 study. Durability of virologic response will be assessed for participants who attained sustained virologic response (SVR) in Part I of this study by performing annual Hepatitis C Virus ribonucleic acid (HCV-RNA) testing. In addition, this study will characterize long-term safety in all participants who received PEG-IFN plus RBV treatment.

Read the detailed description

During the Part 2 LTFU, participants will be evaluated at Years 1, 2, 3, 4, and 5. Each participant's first LTFU visit will be scheduled approximately 1 year after the post-treatment Follow-up Week 24 visit in Part 1 of this study (NCT00104052).

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • must be obtained from the participant or the participant's parent or legal guardian prior to any long-term follow-up study-related procedures. According to local laws and/or IRB/IEC requirements, participants may also need to provide written assent.
  • The participant must have received at least one dose of peginterferon alfa-2b and ribavirin in the Protocol No. P02538 study.
  • The participant must have completed the 24-week post-treatment follow-up in the P02538 Part 1 study. All participants whether sustained responders, relapsers, or nonresponders are eligible to participate.

Exclusion criteria

Exclusion Criteria:

  • Concurrent participation in any other clinical study.
  • Retreatment with any antiviral or immunomodulatory drug for chronic after completion of, or discontinuation from, the treatment phase of the P02538 Part 1 study.
  • Any condition that in the opinion of the Investigator would make the participant unsuitable for enrollment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
94 participants (actual)

Study arms

  • Other
    PEG-IFN + RBV: LTFU

    Pediatric participants who completed treatment with peginterferon alfa-2b (PEG-IFN) plus ribavirin (RBV) in P02538 Part 1 of this study (NCT00104052) were enrolled in a 5-year Long Term Follow-Up (LTFU) during P02538 Part 2 (NCT00761735). No study treatment was administered in Part 2.

    Biological: Peginterferon alfa-2b · Drug: Ribavirin

Interventions

  • In the previous treatment protocol (P02538 Part 1), peginterferon alfa-2b was administered at a dose of 60 μg/m\^2 by subcutaneous injection weekly for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).

    Also known as: PEG-Intron®

  • In the previous treatment protocol (P02538 Part 1), ribavirin was administered at a dose of 15 mg/kg/day orally in two divided doses for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).

    Also known as: REBETOL®

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Relapsed At End of LTFU Year 5

    Relapse was defined as Hepatitis C Virus ribonucleic acid (HCV-RNA) that was above the lower limit of quantitation at Year 5 of the LTFU.

    Time frame: Part 2 LTFU Year 5

  2. Mean Height Percentiles of Participants Over LTFU

    To determine long-term effects of the Part 1 treatment on height, changes in height during the Part 2 LTFU were evaluated using height percentiles based on 2000 Center For Disease Control growth charts for the general population.

    Time frame: Part 1 Pre-treatment Baseline, Part 2 LTFU Year 1, Part 2 LTFU Year 2, Part 2 LTFU Year 3, Part 2 LTFU Year 4, Part 2 LTFU Year 5, Last Available LTFU Visit (up to 5 years)

  3. Mean Weight Percentiles of Participants Over LTFU

    To determine long-term effects of the Part 1 treatment on weight, changes in weight during the Part 2 LTFU were evaluated using weight percentiles based on 2000 Center For Disease Control growth charts for the general population.

    Time frame: Part 1 Pre-treatment Baseline, Part 2 LTFU Year 1, Part 2 LTFU Year 2, Part 2 LTFU Year 3, Part 2 LTFU Year 4, Part 2 LTFU Year 5, Last Available LTFU Visit (up to 5 years)

  4. Mean Body Mass Index (BMI) Percentiles of Participants Over LTFU

    To determine long-term effects of the Part 1 treatment on BMI, changes in BMI during the Part 2 LTFU were evaluated using BMI percentiles based on 2000 Center For Disease Control growth charts for the general population.

    Time frame: Part 1 Pre-treatment Baseline, Part 2 LTFU Year 1, Part 2 LTFU Year 2, Part 2 LTFU Year 3, Part 2 LTFU Year 4, Part 2 LTFU Year 5, Last Available LTFU Visit (up to 5 years)

  5. Mean Age at Attained Tanner Stages (Sexual Maturity) at End of LTFU (Last Observation) By Gender

    The Tanner Stage (TS) defines physical measurements of sexual development based on external primary and secondary sex characteristics. Female participants are evaluated for breast development and pubic hair distribution and male participants are evaluated for genital development and pubic hair distribution, based on a 5-stage ordinal scale ranging from TS 1 (prepubertal/preadolescent characteristics) to TS 5 (mature or adult characteristics). Mean ages for attaining each TS in the normal population have been previously established based on measuring correlating reproductive hormone levels, and are expressed in years as follows for females (F) and males (M): TS 1= 7.1 (F+M); TS 2= 10.5 (F), 12.1 (M); TS 3= 11.6 (F), 13.6 (M); TS 4=, 12.3 (F), 15.1 (M); TS 5= 14.5 (F), 18 (M). To assess sexual maturation at the end of the LTFU (last observation), females and males were staged and the mean age at each TS attained was reported.

    Time frame: Last assessment of the Part 2 LTFU (up to 5 years)

07

Results

Posted Dec 17, 2013

Participant flow

Participant flow — Overall Study
MilestonePEG-IFN + RBV: LTFU
Started94
Completed80
Not completed14
Withdrew: Lost to follow-up6
Withdrew: Withdrawal by subject6
Withdrew: Non-compliance with protocol1
Withdrew: Administrative1

Outcome measures

PrimaryNumber of Participants Who Relapsed At End of LTFU Year 5

Relapse was defined as Hepatitis C Virus ribonucleic acid (HCV-RNA) that was above the lower limit of quantitation at Year 5 of the LTFU.

Time frame:
Part 2 LTFU Year 5
Reported as:
Number · participants
Number of Participants Who Relapsed At End of LTFU Year 5
participantsPEG-IFN + RBV: LTFU (All)
Number of Participants Who Relapsed At End of LTFU Year 50
PrimaryMean Height Percentiles of Participants Over LTFU

To determine long-term effects of the Part 1 treatment on height, changes in height during the Part 2 LTFU were evaluated using height percentiles based on 2000 Center For Disease Control growth charts for the general population.

Time frame:
Part 1 Pre-treatment Baseline, Part 2 LTFU Year 1, Part 2 LTFU Year 2, Part 2 LTFU Year 3, Part 2 LTFU Year 4, Part 2 LTFU Year 5, Last Available LTFU Visit (up to 5 years)
Reported as:
Mean · percentile
Mean Height Percentiles of Participants Over LTFU
percentilePEG-IFN + RBV: LTFU (24 Weeks)PEG-IFN + RBV: LTFU (48 Weeks)
Part 1 Pre-treatment Baseline48.94 ± 27.3852.5 ± 29.98
LTFU Year 1 (n=40, n=44)49.21 ± 29.0343.37 ± 27.87
LTFU Year 2 (n=39, n=39)50.56 ± 29.1846.24 ± 29.19
LTFU Year 3 (n=39, n=44)48.05 ± 28.3846.00 ± 28.24
LTFU Year 4 (n=40, n=38)49.62 ± 30.8745.27 ± 29.44
LTFU Year 5 (n=38, n=42)47.61 ± 29.5743.51 ± 27.57
Last Available LTFU Visit (n=46, n=48)45.96 ± 30.4543.56 ± 27.19
PrimaryMean Weight Percentiles of Participants Over LTFU

To determine long-term effects of the Part 1 treatment on weight, changes in weight during the Part 2 LTFU were evaluated using weight percentiles based on 2000 Center For Disease Control growth charts for the general population.

Time frame:
Part 1 Pre-treatment Baseline, Part 2 LTFU Year 1, Part 2 LTFU Year 2, Part 2 LTFU Year 3, Part 2 LTFU Year 4, Part 2 LTFU Year 5, Last Available LTFU Visit (up to 5 years)
Reported as:
Mean · percentile
Mean Weight Percentiles of Participants Over LTFU
percentilePEG-IFN + RBV: LTFU (24 Weeks)PEG-IFN + RBV: LTFU (48 Weeks)
Part 1 Pre-treatment Baseline52.5 ± 26.8358.56 ± 30.56
LTFU Year 1 (n=40, n=44)53.62 ± 26.7556.38 ± 30.55
LTFU Year 2 (n=39, n=39)51.73 ± 26.8952.03 ± 30.47
LTFU Year 3 (n=39, n=44)53.18 ± 29.1254.26 ± 30.37
LTFU Year 4 (n=40, n=38)51.75 ± 28.9049.50 ± 30.37
LTFU Year 5 (n=38, n=42)51.16 ± 27.1653.12 ± 31.38
Last Available LTFU Visit (n=46, n=48)50.15 ± 28.4455.53 ± 30.67
PrimaryMean Body Mass Index (BMI) Percentiles of Participants Over LTFU

To determine long-term effects of the Part 1 treatment on BMI, changes in BMI during the Part 2 LTFU were evaluated using BMI percentiles based on 2000 Center For Disease Control growth charts for the general population.

Time frame:
Part 1 Pre-treatment Baseline, Part 2 LTFU Year 1, Part 2 LTFU Year 2, Part 2 LTFU Year 3, Part 2 LTFU Year 4, Part 2 LTFU Year 5, Last Available LTFU Visit (up to 5 years)
Reported as:
Mean · percentile
Mean Body Mass Index (BMI) Percentiles of Participants Over LTFU
percentilePEG-IFN + RBV: LTFU (24 Weeks)PEG-IFN + RBV: LTFU (48 Weeks)
Part 1 Pre-treatment Baseline50.4 ± 29.6359.76 ± 31.52
LTFU Year 1 (n=40, n=44)51.15 ± 30.2759.91 ± 31.55
LTFU Year 2 (n=39, n=39)48.11 ± 29.5952.89 ± 30.82
LTFU Year 3 (n=39, n=44)52.14 ± 31.0054.96 ± 30.89
LTFU Year 4 (n=40, n=38)48.44 ± 30.4648.69 ± 31.52
LTFU Year 5 (n=38, n=42)48.61 ± 29.7252.34 ± 31.87
Last Available LTFU Visit (n=46, n=48)48.79 ± 29.4055.38 ± 31.48
PrimaryMean Age at Attained Tanner Stages (Sexual Maturity) at End of LTFU (Last Observation) By Gender

The Tanner Stage (TS) defines physical measurements of sexual development based on external primary and secondary sex characteristics. Female participants are evaluated for breast development and pubic hair distribution and male participants are evaluated for genital development and pubic hair distribution, based on a 5-stage ordinal scale ranging from TS 1 (prepubertal/preadolescent characteristics) to TS 5 (mature or adult characteristics). Mean ages for attaining each TS in the normal population have been previously established based on measuring correlating reproductive hormone levels, and are expressed in years as follows for females (F) and males (M): TS 1= 7.1 (F+M); TS 2= 10.5 (F), 12.1 (M); TS 3= 11.6 (F), 13.6 (M); TS 4=, 12.3 (F), 15.1 (M); TS 5= 14.5 (F), 18 (M). To assess sexual maturation at the end of the LTFU (last observation), females and males were staged and the mean age at each TS attained was reported.

Time frame:
Last assessment of the Part 2 LTFU (up to 5 years)
Reported as:
Mean · years
Mean Age at Attained Tanner Stages (Sexual Maturity) at End of LTFU (Last Observation) By Gender
yearsPEG-IFN + RBV: LTFU (Female)PEG-IFN + RBV: LTFU (Male)
Age of TS 1 participants (n=4, n=5)9.75 ± 1.1311.00 ± 0.80
Age of TS 2 participants (n=5, n=3)11.86 ± 0.7812.53 ± 1.27
Age of TS 3 participants (n=7, n=1)15.26 ± 4.6413.60 ± 0
Age of TS 4 participants (n=4, n=6)16.00 ± 4.3114.75 ± 1.47
Age of TS 5 participants (n=21, n=27)17.37 ± 2.7119.18 ± 2.48

Adverse events

Collected over 5 years, starting after the Part 1 post-treatment Follow-up Week 24 visit. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PEG-IFN + RBV: LTFU—3/94 (3.2%)—
Most frequent serious events
Most frequent serious events
EventPEG-IFN + RBV: LTFU
AppendicitisInfections and infestations2/94
TalipesCongenital, familial and genetic disorders1/94

Baseline characteristics

Age, Continuous
Age, Continuous(years)PEG-IFN + RBV: LTFU
Mean9.9 ± 3.9
Sex: Female, Male
Sex: Female, Male(Participants)PEG-IFN + RBV: LTFU
Female49
Male45
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, Shelton M, Kerkar N, Galoppo M, Pedreira A, Rodriguez-Baez N, Ciocca M, Lachaux A, Lacaille F, Lang T, Kullmer U, Huber WD, Gonzalez T, Pollack H, Alonso E, Broue P, Ramakrishna J, Neigut D, Valle-Segarra AD, Hunter B, Goodman Z, Xu CR, Zheng H, Noviello S, Sniukiene V, Brass C, Albrecht JK. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol. 2010 Apr;52(4):501-7. doi: 10.1016/j.jhep.2010.01.016. Epub 2010 Feb 4. PubMed 20189674 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2008
First posted
Sep 29, 2008
Start
Jul 2007
Primary completionActual
Jan 2013
CompletionActual
Jan 2013
Results first posted
Dec 17, 2013
Last update
Apr 4, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00761735
Responsible party
Sponsor
First posted
Sep 29, 2008
Start date
Jul 2007
Primary completion
Jan 2013
Completion
Jan 2013
Results posted
Dec 17, 2013
Last update
Apr 4, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2b · Ribavirin

Start the discussion